Ectodysplasin A2 Receptor Antikörper

Produktnummer ABIN501133

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch Ectodysplasin A2 Receptor in WB, IHC (p) und EIA. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Ectodysplasin A2 Receptor Antikörper (ABIN501133)

Target: Ectodysplasin A2 Receptor (EDA2R)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Ectodysplasin A2 Receptor Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Produktdetails anti-Ectodysplasin A2 Receptor Antikörper

Spezifität: This antibody detects EDA2R / TNFRSF27.

Kreuzreaktivität (Details): Species reactivity (tested):Human

Aufreinigung: Affiinity chromatography

Immunogen: XEDAR antibody was raised against recombinant human XEDAR.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA. Western blot: 0.5 - 1 μg/mL. Immunohistochemistrry on paraffin sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS containing 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Details zu Ectodysplasin A2 Receptor

Target: Ectodysplasin A2 Receptor (EDA2R)

Andere Bezeichnung: EDA2R / TNFRSF27

Hintergrund: X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2) (1). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappaB and JNK pathways (2). Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis (3). The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment (3).Synonyms: EDA-A2 receptor, Tumor necrosis factor receptor superfamily member 27, UNQ2448/PRO5727/PRO34080, X-linked ectodysplasin-A2 receptor, XEDAR

Gen-ID: 60401